Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Genoa – page 56

715 clinical trials in Genoa, Italy across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Genoa at a glance
715
clinical trials
  • Research sites5
Type of trial
Recruitment status
Quick filters

715 trials in Genoa

Open in trial search

Hormone receptor positive breast cancer+1

Not recruiting

Study of Giredestrant, Triptorelin, and Anastrozole in Premenopausal Women with ER-Positive/HER2-Negative Early Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Anastrozole
  • Sponsor:ETOP IBCSG Partners Foundation

Tuberous sclerosis complex+2

Not recruiting

Study on Cannabidiol Oral Solution for Infants with Tuberous Sclerosis, Dravet Syndrome, or Lennox-Gastaut Syndrome Experiencing Uncontrolled Seizures

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Cannabidiol
  • Sponsor:Jazz Pharmaceuticals Research UK Limited

Hormone-refractory prostate cancer

Not recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Novartis Pharma AG

Breast cancer

Not recruiting

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Neuroblastoma recurrent

Not recruiting

Study of Naxitamab and Sargramostim for High-Risk Neuroblastoma in Patients with Refractory Bone or Bone Marrow Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Naxitamab
  • Sponsor:Y-mAbs Therapeutics A/S

Spinal muscular atrophy

Not recruiting

Study on the Safety and Effects of Risdiplam for Adults and Children with Spinal Muscular Atrophy

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Not recruiting

Study on the Effects of GSK3739937 for Adults with HIV-1 Who Have Not Yet Received Treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:GSK3739937
  • Sponsor:Viiv Healthcare UK Limited

Colorectal cancer metastatic

Not recruiting

Study Comparing Relatlimab-Nivolumab Combination with Regorafenib or Trifluridine-Tipiracil for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Non-small cell lung cancer

Not recruiting

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Peripheral T-cell lymphoma unspecified

Not recruiting

Study on Brentuximab Vedotin and Drug Combination for Patients with Peripheral T-cell Lymphoma with Less Than 10% CD30 Expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Brentuximab Vedotin
  • Sponsor:Seagen Inc.

Cystic fibrosis

Not recruiting

Study on the Effects of Inhaled ETD001 for People with Cystic Fibrosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:3-Amino-N-{[5-[4-[Bis[(2S,3R,4R,5R)-2,3,4,5,6-Pentahydroxyhexyl]Amino]Piperidine-1-Carbonyl]-1,3-Diethyl-Benzimidazol-1-Ium-2-Yl]Methyl}-5H-Pyrrolo[2,3-B]Pyrazine-2-Carboxamide Dihydrochloride Chloride
  • Sponsor:Enterprise Therapeutics Limited

Gastroenteropancreatic neuroendocrine tumour disease

Not recruiting

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Genoa

What the registry says about research in the country

01 Infectious Disease Research

Clinical studies focusing on viral infections and prevention strategies, including trials evaluating vaccines against Herpes Zoster and Cytomegalovirus in healthy adults.

  • Vaccine effectiveness studies
  • Immune response monitoring
  • Prevention protocols

Research includes evaluation of antibiotic protocols in dental procedures and viral-specific treatments for immunocompromised patients.

02 Oncology Studies

Innovative research in cancer treatment, including trials for breast cancer prevention, advanced solid tumors, and targeted therapies for colorectal cancer.

  • Preventive interventions
  • Novel combination therapies
  • Diagnostic imaging

Studies encompass both early intervention strategies and treatments for advanced stages of various cancers.

03 Neurological Disorders

Investigations into treatments for Multiple Sclerosis and other neurological conditions, with focus on disease progression and innovative therapies.

  • Progressive MS treatments
  • Neuromuscular monitoring
  • Safety assessments

Clinical trials evaluating new therapeutic approaches for various neurological conditions including Dravet Syndrome.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.